NEWS and PRESS RELEASES

10 December 2021

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
Read more

04 May 2021

CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing
Read more

17 September 2020

CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach
Read more

9 July 2020

CEBINA identifies a common antihistamine nasal spray as a potential anti-COVID-19 approach
Read more

2 June 2020

Eveliqure Biotechnologies announces regulatory approval to initiate first clinical trial of its ShigETEC vaccine candidate Biotechnologies 
Read more

4 March 2020

Calyxha Biotechnologies announces new financing to support pre-clinical development of its therapeutic lead candidate, CAL-X
Read more

17 August 2021

Widely available anti-allergy azelastine nasal spray poised to revolutionize COVID-19 management
Read more

17 February 2021

URSAPHARM Arzneimittel
and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19
Read more

19 November 2020

Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC
Read more

30 June 2020

Eveliqure secures further private investment to support development of its combined Shigella and ETEC vaccine candidate
Read more

20 April 2020

Calyxha Biotechnologies announces grant of a European Patent on neurodegenerative diseases
Read more

 

5 November 2020

Eveliqure Biotechnologies GmbH announces a grant from the Wellcome Trust to support their effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries
Read more

14 June 2021

CEBINA announces the launch of Danube Labs, a partnership with Evotec to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions
Read more

24 September 2020

Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate
Read more

09 September 2020

Eveliqure announces the award of a NIAID contract to finance Phase 2 clinical studies of its combined Shigella and ETEC vaccine candidate
Read more

4 June 2020

CEBINA secures seed funding for its unique extended spectrum Coronavirus vaccine
Read more

17 April 2020

CEBINA today announces the initiation of several collaborative projects that address the global health crisis caused by the pandemic spread of the SARS-CoV-2 virus
Read more